ClinicalTrials.gg
CompletedNCT06786286Updated Apr 16, 2025

A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects

A Phase 1 interventional study of [14C]-ITI-1284 in Healthy Volunteers, sponsored by Intra-Cellular Therapies, Inc.. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-16.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
30 Years to 55 Years
Sex
Male
01

Study summary

ITI-1284-012 is an open-label, single-dose study to assess the mass balance recovery of radioactivity, and to evaluate the pharmacokinetics, safety and tolerability of ITI-1284 after a single subcutaneous dose of [14C]-ITI-1284 in healthy male subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.

First submitted before Intra-Cellular Therapies, Inc. became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects between 30 and 55 years of age (inclusive);
  • between18.0 and 32.0 kg/m2, inclusive, at screening, and a minimum body weight of 50 kg at screening;
  • Willing to be confined to the clinical research unit for the duration of the inpatient period of the study.

Exclusion criteria

Exclusion Criteria:

  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic X-rays and other medical exposure, exceeding 5 mSev in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker shall participate in the study;
  • Subjects who have been enrolled in a 14C-labeled product study in the 10 months prior to dosing with study drug on Day 1;
  • Any clinical condition or procedure that may affect the absorption, distribution, biotransformation, or excretion of ITI-1284. Subjects with a history of appendectomy and/or abdominal wall hernia repair are eligible for study participation provided surgery was performed ≥1 year ago;
  • Acute diarrhea or constipation in the 7 days before Day 1. If screening occurs > 7 days before Day 1, this criterion will be determined on Day 1;
  • abnormal findings in vital sign assessments, supine SBP > 140 mmHg or \< 90 mmHg, or supine DBP >90 mmHg or \< 50 mmHg or supine pulse rate > 100 bpm or \< 45 bpm at Screening;
  • History of psychiatric condition that in the Investigator's opinion may be detrimental to participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    [14C]-ITI-1284 20 mg

    Drug: [14C]-ITI-1284

Interventions

  • \[14C\]-ITI-1284 20 mg oral solution (not more than 22 μCi), subcutaneous administration

06

What researchers measure

Primary outcomes

  1. Mass balance recovery of total radioactivity in urine and feces combined

    percentage of total radioactivity

    Time frame: Day 1 up to Day 29

  2. Pharmacokinetics: AUC0-t for total radioactivity

    Area under the plasma drug concentration-time curve (AUC) from time zero to the last measurable concentration

    Time frame: Day 1 up to Day 29

  3. Pharmacokinetics: AUC0-t for ITI-1284

    Area under the plasma drug concentration-time curve (AUC) from time zero to the last measurable concentration

    Time frame: Day 1 to Day 8

  4. Pharmacokinetics: Cmax for total radioactivity

    Maximum plasma concentration

    Time frame: Day 1 up to Day 29

  5. Pharmacokinetics: Cmax for ITI-1284

    Maximum plasma concentration

    Time frame: Day 1 to Day 8

  6. Pharmacokinetics: Tmax for total radioactivity

    Time of maximum plasma concentration

    Time frame: Day 1 up to Day 29

  7. Pharmacokinetics: Tmax for ITI-1284

    Time of maximum plasma concentration

    Time frame: Day 1 to Day 8

Secondary outcomes

  1. Percentage of subjects with treatment-emergent adverse events

    Time frame: Up to 30 days after the dose of study drug

  2. Change from baseline in systolic and diastolic blood pressure

    Time frame: Day 14

  3. Change from baseline in ECG QT interval

    Time frame: Day 14

07

Study locations

1 site
  • Clinical Site 1
    Nottingham, NG116JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Mar 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2025
First posted
Jan 22, 2025
StartActual
Jan 28, 2025
Primary completionActual
Mar 26, 2025
CompletionActual
Mar 26, 2025
Last update
Apr 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06786286
Responsible party
Sponsor
First posted
Jan 22, 2025
Start date
Jan 28, 2025
Primary completion
Mar 26, 2025
Completion
Mar 26, 2025
Last update
Apr 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deulumateperone

Start the discussion